Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting
02 Juillet 2024 - 2:00PM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its
participation in the International Society for Stem Cell Research
(ISSCR) Annual Meeting 2024 with a broad range of content covering
the utility of optical genome mapping (OGM) for research,
development, and manufacturing applications in stem cell therapy.
ISSCR’s annual meeting brings together industry, medical, and
academic professionals to discuss advances in stem cell research
and regenerative medicine. The ISSCR conference will be held July
10-13, 2024, in Hamburg, Germany.
As part of a sponsored session titled
“High-resolution genome integrity assessment in stem cell therapy
development with optical genome mapping,” three experts will
discuss the critical role of OGM in assessing the genome integrity
and off-target events in engineered cells, specifically within the
context of stem cell research. Presentations will cover OGM’s
utility for monitoring genomic integrity and off-target
effects in cell lines and its potential to improve the quality,
safety, and overall risk profile of next-generation therapy
development and manufacturing. Dr. Lucia Gallego Villarejo from
Ruhr University Bochum, Dr. Jeanne Loring from Scripps Research
Institute, and Dr. Alicia Bertolotti from Bionano will present in
Hall G2 on Friday, July 12, 2024, at 12:00 PM CEST.
Two scientific posters by Dr. Alex Hastie and Alex
Chitsazan from Bionano, covering the use of OGM in cell
manufacturing and bioprocessing applications, will be on display
during the conference.
Session |
Title |
Presenter |
Presented |
Innovation Session |
High-resolution genome integrity assessment in stem cell therapy
development with optical genome mapping |
Gallego Villarejo L., Loring J., Bertolotti A. |
July 12, 2024 12:00-1:00 PM CEST Hall G2, Level 2 |
Poster Number |
Title |
Presenter |
Presented |
485 |
Genome integrity assessment by optical genome mapping for research
in cell and gene therapy, stem cell, and bioprocessing
applications |
Chitsazan A. |
July 11, 2024 3:45-4:45 PM CEST Poster and Exhibit Hall |
446 |
Genome wide, high-throughput, high-resolution structural variation
detection at low variant allele fraction for cell
bioprocessing |
Hastie A. |
July 11, 2024 4:45-5:45 PM CEST Poster and Exhibit Hall |
|
|
|
|
“We are excited to participate in ISSCR’s annual
meeting and to see content that demonstrates OGM’s utility for
pharmaceutical research and drug development. We believe that OGM
can play a significant role in the development of new methods to
analyze the quality of genome-edited cells, and welcome discussion
of its incorporation into cell and gene therapy workflows,”
commented Erik Holmlin, PhD, president and chief executive officer
of Bionano.
More details on the conference can be found here:
https://bionano.com/isscr-2024/.
About Bionano
Bionano is a provider of genome analysis solutions
that can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
optical genome mapping (OGM) solutions, diagnostic services and
software. The Company offers OGM solutions for applications across
basic, translational and clinical research. The Company also offers
an industry-leading, platform-agnostic genome analysis software
solution, and nucleic acid extraction and purification solutions
using proprietary isotachophoresis (ITP) technology. Through its
Lineagen, Inc. d/b/a Bionano Laboratories business, the Company
also offers OGM-based diagnostic testing services.
For more information, visit www.bionano.com
or www.bionanolaboratories.com.
Except as specifically noted otherwise, Bionano’s
products are for research use only and not for use in diagnostic
procedures.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “believe,” “potential,” “will,”
and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, OGM’s utility in research, development, and
manufacturing processes for monitoring genomic integrity and
off-target effects in cell lines and its potential to improve the
quality, safety, and overall risk profile of next-generation
therapy development and manufacturing; the utility of OGM for
research in the areas reported in the presentations given and the
posters made available at ISSCR’s annual meeting, the growth and
adoption of OGM for use in monitoring genomic integrity and
off-target effects in cell lines, and other statements that are not
historical fact. Each of these forward-looking statements involves
risks and uncertainties. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: global and macroeconomic
events, such as recent and potential bank failures, supply chain
disruptions, global pandemics, inflation, and the ongoing conflicts
between Ukraine and Russian and Israel and Hamas, on our business
and the global economy; general market conditions; changes in the
competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; failure of
for monitoring genomic integrity and off-target effects in
cell lines and its potential to improve the quality, safety, and
overall risk profile of next-generation therapy development and
manufacturing; failure of OGM to be used or prove useful for
monitoring genomic integrity and off-target effects in cell
lines; failure of researchers to adopt OGM; the ability of our OGM
solutions to offer the anticipated benefits for and contributions
to the areas reported in the presentations given and posters made
available at the ISSCR’s annual meeting; future study results
contradicting the results reported in the presentations given and
posters made available at the ISSCR’s annual meeting; changes in
our strategic and commercial plans; our ability to obtain
sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; our ability to effectively manage our uses of
cash, and our ability to continue as a “going concern”; and the
risks and uncertainties associated with our business and financial
condition in general, including the risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including, without limitation, our Annual Report on
Form 10-K for the year ended December 31, 2023 and in other filings
subsequently made by us with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are
based on management’s assumptions and estimates as of such date. We
do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of the receipt of
new information, the occurrence of future events or otherwise.
CONTACTS Company
Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858)
888-7610 eholmlin@bionano.com
Investor Relations: David Holmes
Gilmartin Group +1 (858) 888-7625 IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Bionano Genomics (NASDAQ:BNGO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024